181 related articles for article (PubMed ID: 17503439)
21. Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.
Helenius MA; Savinainen KJ; Bova GS; Visakorpi T
BJU Int; 2006 Feb; 97(2):404-9. PubMed ID: 16430655
[TBL] [Abstract][Full Text] [Related]
22. Expression of ERalpha and ERbeta in prostate cancer.
Linja MJ; Savinainen KJ; Tammela TL; Isola JJ; Visakorpi T
Prostate; 2003 May; 55(3):180-6. PubMed ID: 12692783
[TBL] [Abstract][Full Text] [Related]
23. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
[TBL] [Abstract][Full Text] [Related]
24. Purine-rich element binding protein (PUR) alpha induces endoplasmic reticulum stress response, and cell differentiation pathways in prostate cancer cells.
Inoue T; Maeno A; Talbot C; Zeng Y; Yeater DB; Leman ES; Kulkarni P; Ogawa O; Getzenberg RH
Prostate; 2009 Jun; 69(8):861-73. PubMed ID: 19267365
[TBL] [Abstract][Full Text] [Related]
25. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers.
Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
Clin Cancer Res; 2001 Aug; 7(8):2340-3. PubMed ID: 11489810
[TBL] [Abstract][Full Text] [Related]
26. The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer.
Inoue T; Leman ES; Yeater DB; Getzenberg RH
Prostate; 2008 Jul; 68(10):1048-56. PubMed ID: 18386260
[TBL] [Abstract][Full Text] [Related]
27. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
[TBL] [Abstract][Full Text] [Related]
28. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
29. Amplification of urokinase gene in prostate cancer.
Helenius MA; Saramäki OR; Linja MJ; Tammela TL; Visakorpi T
Cancer Res; 2001 Jul; 61(14):5340-4. PubMed ID: 11454671
[TBL] [Abstract][Full Text] [Related]
30. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
[TBL] [Abstract][Full Text] [Related]
31. Gene amplifications associated with the development of hormone-resistant prostate cancer.
Edwards J; Krishna NS; Witton CJ; Bartlett JM
Clin Cancer Res; 2003 Nov; 9(14):5271-81. PubMed ID: 14614009
[TBL] [Abstract][Full Text] [Related]
32. Silencing of MBD1 and MeCP2 in prostate-cancer-derived PC3 cells produces differential gene expression profiles and cellular phenotypes.
Yaqinuddin A; Abbas F; Naqvi SZ; Bashir MU; Qazi R; Qureshi SA
Biosci Rep; 2008 Dec; 28(6):319-26. PubMed ID: 18666890
[TBL] [Abstract][Full Text] [Related]
33. Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.
Walton TJ; Li G; McCulloch TA; Seth R; Powe DG; Bishop MC; Rees RC
Prostate; 2009 Jun; 69(8):810-9. PubMed ID: 19189301
[TBL] [Abstract][Full Text] [Related]
34. Renin-angiotensin system is an important factor in hormone refractory prostate cancer.
Uemura H; Hasumi H; Ishiguro H; Teranishi J; Miyoshi Y; Kubota Y
Prostate; 2006 Jun; 66(8):822-30. PubMed ID: 16482568
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex.
Wang LG; Johnson EM; Kinoshita Y; Babb JS; Buckley MT; Liebes LF; Melamed J; Liu XM; Kurek R; Ossowski L; Ferrari AC
Cancer Res; 2008 Apr; 68(8):2678-88. PubMed ID: 18413735
[TBL] [Abstract][Full Text] [Related]
36. [Expression of androgen receptor protein in hormone refractory prostate cancer].
Zhang Y; Chen W; Hu XK; Gui ZN
Ai Zheng; 2003 Jan; 22(1):95-7. PubMed ID: 12561446
[TBL] [Abstract][Full Text] [Related]
37. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
Rocchi P; Muracciole X; Fina F; Mulholland DJ; Karsenty G; Palmari J; Ouafik L; Bladou F; Martin PM
Oncogene; 2004 Dec; 23(56):9111-9. PubMed ID: 15489889
[TBL] [Abstract][Full Text] [Related]
38. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
39. Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer.
Ruiz C; Holz DR; Oeggerli M; Schneider S; Gonzales IM; Kiefer JM; Zellweger T; Bachmann A; Koivisto PA; Helin HJ; Mousses S; Barrett MT; Azorsa DO; Bubendorf L
J Pathol; 2011 Mar; 223(4):543-52. PubMed ID: 21294127
[TBL] [Abstract][Full Text] [Related]
40. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
